PRIA Logo™
114-hr-3968114th Congress

Stop Meth Labs and Enhance Patient Access Act of 2015

Sponsored By: Representative Guinta, Frank C. [R-NH-1]

Unknown

Summary

Stop Meth Labs and Enhance Patient Access Act of 2015 This bill amends the Controlled Substances Act to revise the standard used by the Drug Enforcement Administration (DEA) to determine whether to exempt a scheduled listed chemical product from certain applicable requirements. (A scheduled listed chemical product is a nonprescription drug product that contains ephedrine, pseudoephedrine, or phenylpropanolamine.) Currently, the DEA may exempt retail sales of a scheduled listed chemical product from certain requirements (e.g., daily sales limits) if the product cannot be used to illegally manufacture methamphetamine. This bill allows the DEA to exempt retail sales of a scheduled listed chemical product from such requirements if it is not practical by processes known to be employed by clandestine laboratory operators to use the product to illegally manufacture methamphetamine.

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Free to download

Bill Overview

No Economic Impacts Identified for this Bill

Sponsors & CoSponsors

Sponsor

Guinta, Frank C. [R-NH-1]

NH • R

Cosponsors

There are no cosponsors for this bill.

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation